The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma

D. J. Pinato, F. A. Mauri, T. Lloyd, V. Vaira, C. Casadio, R. L. Boldorini, R. Sharma

Research output: Contribution to journalArticle


Background: Recent preclinical studies identified Axl, a tyrosine kinase receptor implicated in tumour progression and epithelial-to-mesenchymal transition, as a putative therapeutic target in malignant pleural mesothelioma (MPM), an invariably fatal malignancy with limited treatment options. Here, we studied the expression of Axl and its ligand Gas-6 (growth arrest signal-6) in primary specimens of MPM, correlating their expression levels with tumour phenotype and clinical outcomes. Methods: Two independent cohorts of consecutive patients diagnosed with MPM were studied: a derivation cohort composed of 63 cases and a validation set of 35 cases. Clinical variables including patients' demographics, tumour stage, histotype, performance status (PS), Axl and Gas-6 staining were tested for predicting overall survival (OS) using univariate and multivariate analyses. Results: In the derivation cohort, Axl (P=0.001) but not Gas-6 overexpression (P=0.35) emerged as a univariate prognostic factor for OS, together with stage (P=0.05), PS (P

Original languageEnglish
Pages (from-to)621-628
Number of pages8
JournalBritish Journal of Cancer
Issue number3
Publication statusPublished - Feb 19 2013


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this